Soligenix, Inc. announced the appointment of Marco Maria Brughera, DVM, Global Head of the Rare Disease Franchise for Sigma-Tau SpA, to its Board of Directors. Since January 2011, Dr. Brughera has held several positions for the Sigma-Tau Group, including Corporate Research and Development Managing Director of Sigma-Tau SpA, President of Sigma-Tau Research and Board Member of Sigma-Tau Pharmaceuticals. He currently serves on the Board of Gentium SpA.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.39 USD | 0.00% | -3.94% | -48.49% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-48.49% | 5.55M | |
+8.29% | 114B | |
+10.21% | 104B | |
-11.90% | 22.41B | |
+0.64% | 22.28B | |
-5.52% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- SNGX Stock
- News Soligenix, Inc.
- Soligenix, Inc. Appoints Marco Maria Brughera to the Board of Directors